Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...

Articles Figures Tables About

Cardiovascular disease gene therapy

Kitamoto S, Egashira K. Anti-monocyte chemoattractant protein-1 gene therapy for cardiovascular diseases. Expert Rev Cardiovasc Ther 2003 1(3) 393 KX). [Pg.232]

Gene therapy holds great promise for the treatment of many diseases (e.g., cancer, AIDS, cystic fibrosis, adenosine deaminase deficiency, cardiovascular diseases, Gaucher disease, a 1-antitrypsin deficiency, rheumatoid arthritis, and several others) (1,2). Advances in genomics and molecular biology have revealed that almost all diseases have a genetic component. In some cases, such as cystic fibrosis or hemophilia,... [Pg.333]

Morishita, R., Higaki, J., Tomita, N. and Ogihara, T. (1998) Application of transcription factor decoy strategy as means of gene therapy and study of gene expression in cardiovascular disease. Circulation Res., 82,1023-1028. [Pg.27]

Table 23.1 Clinical gene therapy trials in cardiovascular disease... Table 23.1 Clinical gene therapy trials in cardiovascular disease...
Gene therapy offers new possibilities for the treatment of cardiovascular diseases. This area of research has focused mainly on the treatment of postangioplasty restenosis, in-stent restenosis, and vein graft thickening. First clinical trials have shown that vascular gene transfer to humans is generally safe and well tolerated. Even... [Pg.454]

MIKKO P.TURUNEN, MIKKO O.HILTUNEN AND SEPPO YLA-HERTTUALA Gene therapy for cardiovascular disease... [Pg.488]

V. J. Dzau, M. Mann, R. Morishita, and Y. Kaneda, Fusigenic viral liposome for gene therapy in cardiovascular diseases, Proc. Natl. Acad. Sci. USA 93 11421 (1996). [Pg.264]

In general, there are a wide variety of circumstances in which some form of cardiovascular gene therapy can play an essential role in the management of the patient with cardiovascular disease. Some situations may call for the short-term expression of a gene in a... [Pg.234]

Angiogenesis, or growth of new blood vessels, appears essential in revascularization after myocardial infarction as well as in treating coronary artery disease and peripheral artery disease. Therefore, cardiovascular gene therapy has concentrated on vascular endothelial growth factor (VEGF) in these diseases (Table 6). [Pg.375]

See other pages where Cardiovascular disease gene therapy is mentioned: [Pg.156]    [Pg.8]    [Pg.113]    [Pg.13]    [Pg.13]    [Pg.139]    [Pg.228]    [Pg.242]    [Pg.272]    [Pg.448]    [Pg.460]    [Pg.460]    [Pg.460]    [Pg.461]    [Pg.461]    [Pg.463]    [Pg.463]    [Pg.465]    [Pg.465]    [Pg.465]    [Pg.466]    [Pg.467]    [Pg.468]    [Pg.511]    [Pg.225]    [Pg.226]    [Pg.363]    [Pg.368]    [Pg.368]    [Pg.434]    [Pg.667]    [Pg.113]    [Pg.476]    [Pg.278]    [Pg.2794]    [Pg.322]    [Pg.331]    [Pg.377]   
See also in sourсe #XX -- [ Pg.241 , Pg.242 ]



SEARCH



Cardiovascular disease

Disease genes

Disease therapy

Gene and Cell-based Therapies for Cardiovascular Disease

Gene disease genes

Gene therapy

© 2024 chempedia.info